Company Overview
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Why Investors Should Care
Return on capital employed stands at 15.8%.
Revenue has grown at a 59.7% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.29B (+10.4% YoY); net profit $58.52M.
- Trailing 12 Months Year-on-year growth — revenue +1.4%, earnings +70.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 59.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 59.73% |
| 1 Year: | 1.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 70.60% |
Stock Price Performance
| 1 Year: | +12.49% |
| 6 Months: | +41.67% |
| 3 Months: | +0.31% |
| 1 Month: | -14.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.70 · Neutral
P/E of 33.69 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 59.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY Progyny, Inc. R2KR3KPHARMA | 25.94 | 33.69 | $2.03B | 0.00% | 15.79% | 14.94% | 59.73% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 122.13M | 128.65M | 122.28M | 127.55M | 172.22M | 195.00M | 205.37M | 214.32M | 258.39M | 279.37M | 280.89M | 269.94M | 278.08M | 304.09M | 286.62M | 298.43M | 324.04M | 332.87M | 313.35M | 318.40M | 328.50M | 350.51M |
| Gross Profit | 3.93M | 5.04M | 5.05M | 5.42M | 9.96M | 11.45M | 12.32M | 11.77M | 16.60M | 11.96M | 20.84M | 20.67M | 28.91M | 29.62M | 28.49M | 25.11M | 32.95M | 43.89M | 45.99M | 44.49M | 58.64M | 60.64M | 62.62M | 56.89M | 62.41M | 68.28M | 59.24M | 63.43M | 75.80M | 78.97M | 72.83M | 76.88M | 83.07M | 89.30M |
| Operating Income | -1.84M | -317.00K | -587.00K | -703.00K | 3.11M | 2.35M | 3.07M | 1.14M | 3.43M | -1.07M | 4.83M | 1.16M | 11.81M | 11.66M | 9.06M | -188.00K | -58.00K | 8.84M | 11.26M | 3.31M | 15.01M | 15.18M | 18.19M | 13.80M | 18.52M | 20.69M | 12.46M | 15.79M | 24.17M | 24.36M | 21.53M | 15.22M | 35.38M | 40.00M |
| Net Income | 4.15M | -831.00K | -1.14M | -1.52M | 2.52M | 1.52M | -8.21M | -4.40M | 3.63M | -1.06M | 4.82M | 39.07M | 15.17M | 18.73M | 16.80M | 15.08M | 4.97M | 8.77M | 13.21M | 3.41M | 17.68M | 14.99M | 15.90M | 13.47M | 16.90M | 16.48M | 10.42M | 10.53M | 15.06M | 17.11M | 13.86M | 12.48M | 24.23M | 28.05M |
| Diluted EPS | - | - | - | - | 0.01 | - | -1.10 | -0.07 | 0.04 | -0.01 | 0.05 | 0.39 | 0.15 | 0.19 | 0.17 | 0.15 | 0.05 | 0.09 | 0.13 | 0.03 | 0.18 | 0.15 | 0.16 | 0.13 | 0.17 | 0.17 | 0.11 | 0.12 | 0.17 | 0.19 | 0.15 | 0.14 | 0.29 | 0.34 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50M | - | 2.60M | - | 2.80M | 3.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.58M | 105.40M | 229.68M | 344.86M | - | 786.91M | 1.09B | 1.17B | 1.29B |
| Cost of Revenue | - | - | - | - | - | 619.59M | 849.80M | 913.86M | 984.18M |
| Gross Profit | 7.40M | 19.43M | 45.51M | 70.06M | - | 167.32M | 238.80M | 253.36M | 304.48M |
| Operating Expenses | - | - | - | - | - | 143.98M | 176.62M | 185.91M | 219.21M |
| Operating Income | -11.01M | -3.45M | 9.68M | 8.35M | - | 23.34M | 62.18M | 67.45M | 85.28M |
| EBITDA | - | - | - | - | - | 24.94M | 64.47M | 70.63M | 90.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | 24.44M | 70.69M | 83.20M | 95.43M |
| Tax Provision | - | - | - | - | - | -5.92M | 8.65M | 28.87M | 36.91M |
| Net Income | -12.45M | 661.00K | -8.57M | 46.46M | - | 30.36M | 62.04M | 54.34M | 58.52M |
| Diluted EPS | -2.37 | 0.04 | -0.41 | 0.47 | - | 0.30 | 0.62 | 0.57 | 0.65 |
| R&D Expense | - | - | - | - | - | - | - | - | 9.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 41.32M | 150.43M | 253.93M | 358.06M | 542.99M | 756.62M | 607.10M | 742.43M |
| Total Equity | -97.62M | -95.11M | 114.27M | 166.95M | 251.82M | 376.97M | 553.43M | 422.06M | 516.04M |
| Cash & Equivalents | - | 127.00K | 80.38M | 70.31M | 91.41M | 120.08M | 97.30M | 162.31M | 112.24M |
| Total Liabilities | - | 30.20M | 36.16M | 86.98M | 106.24M | 166.02M | 203.19M | 185.04M | 226.39M |
| Current Liabilities | - | 30.20M | 36.16M | 77.79M | 98.82M | 159.54M | 185.95M | 168.63M | 202.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.47M | 2.27M | -1.53M | 36.20M | 26.04M | 80.39M | 188.81M | 179.10M | 210.19M |
| Investing Cash Flow | -612.00K | 1.90M | -2.76M | -40.03M | 8.77M | -43.87M | -200.53M | 195.79M | -159.01M |
| Financing Cash Flow | 11.77M | -8.74M | 84.55M | -6.25M | -13.70M | -7.86M | -11.07M | -309.88M | -99.36M |
| Capital Expenditure | -612.00K | -579.00K | -2.96M | -1.04M | -2.13M | -3.24M | -3.64M | -5.41M | -18.41M |
| Free Cash Flow | -10.09M | 1.69M | -4.49M | 35.17M | 23.91M | 77.15M | 185.17M | 173.70M | 191.78M |
| Share Buybacks | - | 1.21M | 185.00K | - | - | 0 | 0 | 300.28M | 81.66M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 15.2% | 18.4% | 19.8% | 20.3% | - | 21.3% | 21.9% | 21.7% | 23.6% |
| Operating Margin % | -22.7% | -3.3% | 4.2% | 2.4% | - | 3.0% | 5.7% | 5.8% | 6.6% |
| Net Margin % | -25.6% | 0.6% | -3.7% | 13.5% | - | 3.9% | 5.7% | 4.7% | 4.5% |
| ROE % | 12.8% | -0.7% | -7.5% | 27.8% | - | 8.1% | 11.2% | 12.9% | 11.3% |
| ROCE % | - | -31.0% | 8.5% | 4.7% | - | 6.1% | 10.9% | 15.4% | 15.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.12% | 11.60M | $301.60M |
| 2 | FMR, LLC | 9.13% | 7.00M | $182.11M |
| 3 | Vanguard Portfolio Management LLC | 6.54% | 5.02M | $130.51M |
| 4 | Vanguard Capital Management LLC | 4.18% | 3.21M | $83.48M |
| 5 | State Street Corporation | 3.94% | 3.02M | $78.59M |
| 6 | Ameriprise Financial, Inc. | 3.60% | 2.76M | $71.85M |
| 7 | Fort Washington Investment Advisors, Inc. | 3.32% | 2.55M | $66.25M |
| 8 | Geode Capital Management, LLC | 2.57% | 1.97M | $51.20M |
| 9 | Citadel Advisors Llc | 2.33% | 1.79M | $46.43M |
| 10 | Dimensional Fund Advisors LP | 2.20% | 1.69M | $43.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PGNY
Progyny (PGNY) Stock Trades Near Fair Value While Broader Checks Hint Discount - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNZ3JZOHE4cWRjay1OQXhodVlhdHFjX3VudTZRNVlIaGRVSmdfUExkVEgwaUppLTg1NDNUbUJabzRkN3pqeVlTZzRoMHhWMTM3Z2VvRnJzbHpianJsU1lnRzNEc0pJdDRUNnRJZ001ZFpMRW1ORW1wSUNMNFZuZ0ExcUlFblk0V3d3dV9qWU…
Wells Fargo's healthcare conference will feature Progyny's finance chief Sept. 8 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNM2owSjVhYlZhNWFVYkZPTVNGUDJUQlUxYnp2RE9JdkNfbUlrbFd4MUtFSzBkX2FScms0Z3JNVXp2S0Z5SW9GeDNwSjBBY1dncklOa3E5cTZHUVVTaUgxdTV1Q1F4ZU9TQ082RGNxSzhxQlVpTG5CSGlDdHpnUTh3QU1oQ0VoclNkNm5KNz…
Progyny: Slow But Consistent Growth With A Pristine Balance Sheet (NASDAQ:PGNY) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOaVpMUHVUVzB2SmxYaEVVdGZqZ3FPX1ZIem5IZU9pb25WeEs2Nm9SVlV1SVhxMDJySFU0WkFzWGg4bVNhODdfSFFCSlc3RnMxaU95Q2FTeWlFbjVTZ1RXdUJpLWE3ejdfcVplb1dNVjJJQ083RjViV2ZSTDlRNHpZanhjQWZIWTlDV21JSG…
Progyny (PGNY) Stock May Be 50% Undervalued On Fresh Analyst Upgrades - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNa2V1V18wdlBUUmVWNUgyRGRQR0ctRF9EZzlWU1hXTE1DVzdORWtvNGRMUFJqek1FNE9HRHNtQmU5aFRJZGRZcjFHUDQ3UFlsRHVuenVzZlViMGQ3RHhDWnFUblhKQ2lFdU0taWp0TFJEeVlKdzRVaU5WVEdhWFQwazBDdlBkUGJ3dHRIUk…
Progyny’s (NASDAQ:PGNY) Q2 CY2026: Beats On Revenue But Stock Drops 10.2% - StockStory
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQTUhTejlUdHFkcDVkelJWS1U1ZGpmZU4xMGJtVzVTVlZTMi1WQ3JSeGtLbGJMQnd4X0loSXJHMlBDR2owQ25GNWZmaTNaUndHaW5jNThLNzNYSlVrOWtXNWo0RnJQVk1Pak80NXFYQnIzUlI0MkVRUVJDU1I5QWlXNXMyUERSVVdLa3Z0aT…
Avoiding Lag: Real-Time Signals in (PGNY) Movement - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPQlRSRG9tcVVpX0FTZjVJR1ZBYlVjcjhhVjYydGlhUEpWcHhmaTNXY1J3azRMMjdNd2RBemxQc0UwTlBPMXV2MXN1QTR6TV8xRTh0VjlMWXNzcXJXVkV3cE9SMk40UzdnRlFkdTZuMTFsRHE3VHluTE44OEY0dXdPWmZ5OVhydHNmVFNIZD…
PGNY — Frequently Asked Questions
What is the current share price of Progyny, Inc. (PGNY)?
As of 2026-09-07 16:24 PDT, Progyny, Inc. (PGNY) trades at $25.94 on NasdaqGS. Its 52-week range is $16.30 to $32.36.
What is the market capitalisation of PGNY?
Progyny, Inc. (PGNY) has a market capitalisation of $2.03B on NasdaqGS.
What is the P/E ratio of PGNY?
PGNY trades at a trailing price-to-earnings (P/E) ratio of 33.69. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 4.97.
What is the return on equity (ROE) of PGNY?
PGNY has a return on equity (ROE) of 14.94%. Its return on capital employed (ROCE) is 15.79%.
Is PGNY a good stock to buy?
This page provides a data-driven analysis of Progyny, Inc. (PGNY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.